In February 2025, a medical team at UCSF delivered the first personalized CRISPR therapy to an infant with CPS1 deficiency, a rare metabolic disorder that prevents the body from breaking down ammonia. The treatment was designed specifically for that child's genetic mutation, built from scratch as a one-time intervention outside any clinical trial.

For families navigating rare pediatric diagnoses, that news raises the question everyone asks: does this apply to my child?

The short answer is that most children with rare disorders won't qualify for personalized CRISPR therapy in the next few years. But the infrastructure being built right now, including the research centers, clinical trials, and specialized expertise at major children's hospitals, will determine which conditions move from "in development" to "available" over the next decade. Knowing where that infrastructure exists and what questions to ask your care team matters more than following every breakthrough announcement.

What CRISPR Does and What It Doesn't Fix

CRISPR is a gene editing tool. It cuts DNA at a specific location and either removes a faulty segment, inserts a corrected one, or turns a gene on or off. When it works, it addresses the genetic cause of a disease rather than managing symptoms.

That precision is what makes it powerful for rare disorders. Many of these conditions are caused by a single mutation in a known gene. If you can fix that mutation, you can stop the disease progression.

But CRISPR doesn't work for every rare disorder. It's most effective when the genetic cause is well understood, the mutation can be corrected without unintended side effects, and the treatment can reach the affected cells. Conditions caused by multiple genes interacting, or by mutations scattered across the genome, are harder to address with current editing techniques.

The CPS1 deficiency case worked because the mutation was pinpointed, the gene's function was known, and the editing could be done in liver cells that were then transplanted back into the infant. That's a narrow set of conditions to meet.

Where Pediatric CRISPR Trials Are Happening Right Now

As of early 2026, there are roughly 250 active gene-editing clinical trials globally. Not all of them use CRISPR. Not all of them are pediatric. And not all rare disorders have a trial open yet.

The UCSF Center for Pediatric CRISPR Cures, launched with $20 million in funding, is one of the few programs explicitly focused on developing these therapies for children with rare conditions. Other academic medical centers with active gene-editing programs include Boston Children's Hospital, Children's Hospital of Philadelphia, and Great Ormond Street Hospital in London.

The conditions currently in pediatric trials include sickle cell disease, beta-thalassemia, certain inherited vision loss disorders, Duchenne muscular dystrophy, and a handful of ultra-rare metabolic conditions. Those are the early targets because the genetics are well mapped and the patient populations are large enough to support trial enrollment.

If your child's diagnosis isn't on that list, it doesn't mean CRISPR won't eventually be an option. It means the research timeline is longer.

What the Timeline from Diagnosis to Treatment Looks Like

Most families first hear about CRISPR in the context of research announcements or fundraising campaigns. What those headlines don't include is the gap between "in trials" and "available to patients outside a trial."

Here's the realistic sequence.

First, your child needs a confirmed genetic diagnosis.

That requires genetic testing, typically chromosomal microarray or whole genome sequencing. If the mutation isn't identified, trial eligibility is off the table.

Second, a research team needs to be actively studying that specific mutation. Not every rare disorder has a dedicated lab working on it. Some do. Many don't.

Third, if a trial exists, your child has to meet enrollment criteria. That often includes age ranges, disease stage, and geographic proximity to the trial site. Some trials require families to relocate for months. Some don't accept patients who are already on certain medications.

Fourth, you get into the trial. Wait times vary. Some trials fill their enrollment slots in weeks. Others stay open for years because they can't find enough eligible patients.

Fifth, the treatment happens. Some gene therapies require one infusion. Others require a series of procedures over weeks or months. And for personalized therapies like the UCSF infant case, it's months of preparation before the treatment is even ready.

Sixth, you wait to see if it works. Early-phase trials are designed to test safety, not efficacy. Later-phase trials measure outcomes, but those results can take years to fully understand. The path is slow and the timeline varies widely by condition.

How to Find Out If Your Child Might Qualify

If your child has a rare disorder and you want to know whether gene therapy is an option, start with these three questions for your medical team:

Has the genetic mutation been identified?

If not, ask about genetic counseling and testing options. A diagnosis is the prerequisite for everything else.

Is there an active research program studying this condition?

Your child's geneticist or rare disease specialist will know if labs are working on it. They can also point you to patient advocacy groups that track trial pipelines.

Are there open trials we could apply for?

ClinicalTrials.gov is the public registry. Your care team can search it for you and explain eligibility requirements.

Some families also join patient registries for their child's specific condition. Registries don't guarantee trial access, but they make it easier for researchers to contact families when new studies open.

What the AAP Says About Genetic Testing for Rare Disorders

The American Academy of Pediatrics updated its guidelines in 2025 to recommend chromosomal microarray as a first-tier test for children with global developmental delay or intellectual disability, alongside exome sequencing in cases where the cause isn't immediately clear.

That matters because many rare disorders present first as developmental delays. The earlier a genetic cause is identified, the earlier families can connect with specialists, enroll in research programs, and plan for what's ahead.

If your child hasn't had genetic testing yet and their diagnosis is unclear, ask your pediatrician about a referral to a genetic counselor. Counselors explain what tests are available, what they'll show, and what the results mean for your family.

What Families Should Expect Over the Next Five Years

Gene editing for pediatric rare disorders is moving from academic proof-of-concept to clinical infrastructure. The UCSF center isn't the only one. More programs are being funded. More trials are opening. More conditions are moving into the pipeline.

That doesn't mean every rare disorder will have a treatment option by 2030. It means the number of families with access is going to grow, and the conditions being prioritized are the ones where the genetics are simplest and the patient advocacy is strongest.

If you're navigating this right now, the most useful thing you can do is get connected to the infrastructure that already exists. Find out if your child's condition has an active research program. Get on the registry if one exists. Build a relationship with a geneticist who knows what trials are opening and which ones your child might qualify for.

The breakthrough announcements will keep coming. What matters more is whether your family is positioned to act when a trial opens that matches your child's diagnosis.

FAQ

What is the difference between CRISPR and traditional gene therapy?

Traditional gene therapy adds a working copy of a gene without removing the faulty one. CRISPR edits the DNA itself, either correcting the mutation or turning genes on and off. Both are forms of gene therapy, but CRISPR is more precise.

Can CRISPR cure any rare disease?

No. It works best for conditions caused by a single known mutation in a gene that can be safely edited. Complex conditions involving multiple genes or unknown mutations aren't good candidates yet.

Is CRISPR therapy covered by insurance?

Most CRISPR treatments are still in clinical trials, which means the trial sponsor covers the cost. If a therapy is FDA-approved, insurance coverage depends on your plan and whether the treatment is deemed medically necessary.

How do I find out if there's a CRISPR trial for my child's condition?

Start with ClinicalTrials.gov and search your child's diagnosis. Your geneticist or rare disease specialist can also help identify trials and explain eligibility.

Are there risks to CRISPR therapy?

Yes. Off-target effects, where the editing tool makes unintended changes to the genome, are a known risk. That's why trials move slowly and safety is monitored closely. Your care team will explain the specific risks for any trial your child is considering.

What should I ask my child's doctor if I'm interested in gene therapy?

Ask three things: Has my child's mutation been identified? Is there research happening on this condition? Are there trials we could apply for? Those answers will tell you whether this is a realistic option right now or something to revisit in a few years.